恩度联合顺铂胸腔内灌注治疗非小细胞肺癌恶性胸腔积液的疗效  

Efficacy of Endu Combined with Cisplatin Intrapleural Perfusion in the Treatment of Non-small Cell Lung Cancer with Malignant Pleural Effusion

作　　者：苏凝 樊利萍 秦丽丽 鲁彩花 SU Ning;FAN Li-ping;QIN Li-li;LU Cai-hua(Department of Respiratory and Critical Care Medicine,Jincheng People's Hospital,Jincheng 048000,Shanxi,China)

机构地区：[1]晋城市人民医院呼吸与危重症医学科,山西晋城048000

出　　处：《医学信息》2021年第11期155-157,共3页Journal of Medical Information

摘　　要：目的分析恩度联合顺铂胸腔内灌注治疗非小细胞肺癌恶性胸腔积液的疗效。方法选取2018年6月~2020年9月我院收治的60例非小细胞肺癌恶性胸腔积液患者作为研究对象,按照随机数字表法分为观察组和对照组,各30例。对照组予以顺铂治疗,观察组在对照组基础上联合恩度治疗,比较两组临床疗效、健康状况、胸腔积液血管内皮生长因子(VEGF)、低氧诱导因子-1(HIF-1α)水平及不良反应发生情况。结果观察组ORR率、DCR率均高于对照组(76.67%vs 40.00%)、(93.33%vs66.67%),差异有统计学意义(P<0.05)。观察组KPS评分高于对照组[(83.45±6.14)分vs(76.58±6.85)分],差异有统计学意义(P<0.05)。观察组VEGF、HIF-1α低于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论恩度联合顺铂胸腔内灌注治疗非小细胞肺癌恶性胸腔积液近期疗效确切,能够有效消除患者胸腔积液,提高患者生活自理能力,且无严重不良反应。Objective To analyze the efficacy of Endo combined with cisplatin intrapleural perfusion in the treatment of malignant pleural effusion of non-small cell lung cancer.Methods 60 patients with malignant pleural effusion of non-small cell lung cancer who were admitted to our hospital from June 2018 to September 2020 were selected as the research objects.According to the random number table method,they were divided into a observation group and a control group,with 30 cases in each group.The control group was treated with cisplatin,and the observation group was treated with Endo on the basis of the control group.The clinical efficacy,health status,pleural effusion vascular endothelial growth factor(VEGF),hypoxia inducible factor-1(HIF-1α)levels and the occurrence of adverse reactions were compared between the two groups.Results The ORR rate and DCR rate of the observation group were higher than those of the control group(76.67%vs 40.00%)and(93.33%vs 66.67%),the difference was statistically significant(P<0.05).The KPS score of the observation group was higher than that of the control group[(83.45±6.14)points vs(76.58±6.85)points],the difference was statistically significant(P<0.05).VEGF and HIF-1αin the observation group were lower than those in the control group,the difference was statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Endo combined with cisplatin intrapleural perfusion in the treatment of non-small cell lung cancer malignant pleural effusion has a definite short-term curative effect.It can effectively eliminate the patient’s pleural effusion and improve the patient’s ability to take care of themselves without serious adverse reactions.

关 键 词：恩度 顺铂 胸腔内灌注 非小细胞肺癌 恶性胸腔积液 

分 类 号：R734.2[医药卫生—肿瘤]